Closing the Postfracture Care Gap Using Administrative Health Databases: Design and Implementation of a Randomized Controlled Trial

The P2X7 loss-of-function Glu496Ala polymorphism affects ex vivo cytokine release and protects against the cytotoxic effects of high ATP-levels

“…Cytokines released during immune responses are known to affect the bone metabolism, and dysregulated cytokine responses are implicated in bone disease such as osteoporosis. IL-1β as well as TNF-α and IL-6 are known to promote osteoclastogenesis either by increasing osteoclast generation and activation or by inducing RANKL expression by osteoblasts [35,36], whereas IL-10 and IFN-γ are known to be inhibitors of osteoclastogenesis by blocking RANKL signalling, either directly or indirectly [35]. Alterations in cytokine release due to the Glu496Ala polymorphisms leading to loss of P2X 7 receptor function might therefore contribute to the development of osteoporosis.…”

Closing the gap in postfracture care at the population level: a randomized controlled trial

“…The design and implementation of this study has been previously described. 11 Briefly, eligible men and women 50 years of age or older with a recently reported fracture of the hip, spine, humerus or forearm were randomized to one of three groups. The intervention consisted of a mailed letter to primary care physicians, or to patients and primary care physicians, notifying them of the recent fracture and suggesting follow-up for the assessment of osteoporosis.…”